Details for Patent: 9,060,940

Title:	Controlled release hydrocodone
Abstract:	A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
Inventor(s):	Oshlack; Benjamin (New York, NY), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John K. (Old Tappan, NJ), Tonelli; Alfred (Congers, NY)
Assignee:	Purdue Pharma L.P. (Stamford, CT)
Filing Date:	Mar 14, 2014
Application Number:	14/210,565
Claims:	1. cited by applicant . Eur. J. Pharm. Sci. Jul. 1999; 8(3):157-9. cited by applicant . Shah et al., J. Cont. Rel. (1989) 9:169-175. cited by applicant . Brendenberg "New Concepts in Administration of Drugs in Tablet Form: Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption and Presentation of an Individualized Dose Administration System Acta Universitiatis Upsaliensis." Comprehensive Summaries of Uppsa/a Dissertations from the Faculty of Pharmacy 287 83 pp. Uppsala ISBN 91-554-5600-6 (2003). cited by applicant . Frohof-Hulsmann et al., "Aqueous Ethyl Cellulose Dispersion Containing Plasticizers of Different Water Solubility and Hydroxypropyl Methyl-Cellulose as Coating Material for Diffusion Pellets II: Properties of Sprayed Films", European Journ. of Pharma and Biopharma., vol. 48, pp. 67-75, 1999. cited by applicant . Gustafsson et al., "Characterisation of Particle Properties and Compaction Behaviour of Hydroxypropyl Methylcellulose with Different Degrees of Methoxy/Hydroxypropyl Substitution", EP Journ of Pharmaceutical Sci. 9, pp. 171-184, 1999. cited by applicant . Hyppola et al.,"Evaluation of Physical Properties of Plasticized Ethyl Cellulose Films Cast From Ethanol Solution Part 1", International Journ. of Pharma., vol. 133, pp. 161-170, 1996. cited by applicant . Physician's Desk Reference 57th ed. 2003 p. 1184-1185 (package insert information for ACTIQ). cited by applicant . Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain: A Randomized, Placebo-Controlled Study", ASRA 06, Final Abstract, Submitted Aug. 4, 2007. cited by applicant . Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain", Current Medical Research and Opinion, vol. 23(7), pp. 223-233, 2007. cited by applicant . Siepmann et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", Journ. of Pharmaceutical Sciences, vol. 88, No. 1, pp. 65-72, Jan. 1999. cited by applicant . Sung et al., "Effect of Formulation Variables on Drug and Polymer Release from HPMC-Based Matrix Tablets", International Journ. of Pharmaceutics vol. 142, pp. 53-60, 1996. cited by applicant . Vashi et al., "Clinical Pharmacology and Pharmacokinetics of Once-Daily Hydromorphone Hydrochloride Extended-Release Capsules", J. Clin. Pharmacal, vol. 45, pp. 547-554, 2005. cited by applicant . Viriden et al., "Investigation of Critical Polymer Properties for Polymer Release and Swelling of HPMC Matrix Tablets", EP Journal of Pharmaceutical Sciences 36, pp. 297-309, 2009. cited by applicant . Webster, PTI-821: Sustained-Release Oxycodon Investig. Drugs, vol. 16, (3), pp. 1-8, 2007. cited by applicant . International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035767 dated Nov. 13, 2012. cited by applicant . International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035768 dated Nov. 13, 2012. cited by applicant . International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035770 dated Nov. 13, 2012. cited by applicant . International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/025914 dated Aug. 28, 2012. cited by applicant . International Search Report and Written Opinion for PCT/US2007/020041, dated Feb. 25, 2008. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on Nov. 3, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Oct. 7, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Jun. 23, 2014. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on May 12, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Feb. 6, 2014. cited by applicant . The Advisory Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014. cited by applicant . The Advisory Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2014. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2014. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 12/982,386 on Apr. 18, 2013. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012. cited by applicant . The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on Nov. 5, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Oct. 3, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Jun. 24, 2014. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on May 9, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Feb. 6, 2014. cited by applicant . The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/483,395 on Oct. 3, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 14/483,395 on Oct. 9, 2014. cited by applicant . The claims pending in U.S. Appl. No. 14/483,395 on Nov. 17, 2014. cited by applicant . The claims pending in U.S. Appl. No. 14/094,968 on Nov. 17, 2014. cited by applicant . The claims pending in U.S. Appl. No. 12/982,386 on Nov. 17, 2014. cited by applicant . The claims pending in U.S. Appl. No. 13/833,263 on Nov. 17, 2014. cited by applicant . An English translation of the Office Action issued in connection with Israeli Patent Application No. 155,637 on Nov. 16, 2014. cited by applicant . An English translation of the Decision on Reexamination issued in connection with Chinese patent application No. 200910132824.3 on Nov. 5, 2014. cited by applicant . The Office Action issued in connection with Chinese Patent Application No. CN 201210130057.4 on Oct. 11, 2014. cited by applicant . English Abstract of JP-08157392-A, Jun. 18, 1996. cited by applicant . Adv. Drug Deliv. Rev. Mar. 1999 I; 36(1):125-141. cited by applicant . Drugs Jan. 1999; 57(1 ):93-9. cited by applicant . Johnson, Sarah J., "Opioid Safety in Patients With Renal or Hepatic Dysfunction" Pain Treatment Topics pp. 1-9 (Release date Jun. 2007; updated Nov. 30, 2007). cited by applicant . Emami, J. et al, "In vitro--In vivo Correlation: From Theory to Applications", J. Pharm Pharmaceut Sci, (www.cspsCanada.org) 9 (2), 169-189, 2006. cited by applicant . Lippold, B. C., Constant or Pulsed Delivery of Active Substance?, Pharmacie in uns Zeit, Jan. 13-31, 1990, No. 1. cited by applicant . Clin. Neuropharmacol Jan.-Feb. 1999; 22 (1):33-9). cited by applicant . Clin. Phannacokinet Sep. 1998; 35(3):173-90. cited by applicant . Conte. et al., Drug Del.. Ind. Pharm. (1989) 15:2583-2596. cited by applicant . J. Control Release Aug. 5, 1999; 60(2-3):391-7. cited by applicant . J. Pharm. Pharmacol Dec. 1996; 48(12):1276-84. cited by applicant . J. Pharm. Sci. Feb. 1993; 82(2):113-26. cited by applicant . Zimm et al., Pharmaceutical Development and Technology, 1(1), 37-42 (1996) "Drug Release from a Multiparticulate Pallet System." cited by applicant . The Merck Index, eleventh edition, pp. 757 and 1100 (1989). cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 945.7. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 984.6. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 181 032.3. cited by applicant . European Search Report issued on Nov. 9, 2010 in connection with European Application No. 10180945.7-2123. cited by applicant . English Translation of the Office Action issued on Mar. 22, 2011 in connection with Japanese Patent Application No. 2006-3165067. cited by applicant . M.H. Beers: "The Merck Index, 11.sup.th edition," 1989, Merck & Co. CP002606249. cited by applicant . Merk Index, 13.sup.th edition, entry 4806: hydrocodone (2001). cited by applicant . EPI Journal Feb. 2007, pp. 59-60; David Harrison; "Divisional Application a continuing problem" (2007). cited by applicant . Document CA/PL 17/07; "Misuse of Divisional Applications," by the EPO President, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Oct. 5, 2007. cited by applicant . Document CA/PL 3/08, presented by epi and other Professional Representatives, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Feb. 14, 2008. cited by applicant . Summons to Attend Oral Proceedings issued in connection with European Patent Application No. 05019453.9 on Jul. 23, 2010. cited by applicant . English translation of Office Action issued by Japanese Patent Office in connection with corresponding Japanese Patent Application No. 2001-534353 on May 25, 2010. cited by applicant . The Office Action issued in connection with Japanese patent application No. 2013-168584 on Sep. 16, 2014. cited by applicant . Claims Pending in U.S. Appl. No. 12/982,386 on Oct. 20, 2014. cited by applicant . Claims Pending in U.S. Appl. No. 13/833,263 on Oct. 20, 2014. cited by applicant . Claims Pending in U.S. Appl. No. 14/094,968 on Oct. 20, 2014. cited by applicant . Claims Pending in U.S. Appl. No. 14/483,395 on Oct. 20, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2013. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2013. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 27, 2012. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012. cited by applicant . The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012. cited by applicant . Santus G., and Baker. R.W., "Osmotic drug delivery: a review of the patent literature," J Controlled Release (1995) vol. 35 pp. 1-21. cited by applicant . Hansch C et al.,"Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics," Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Oxford, Pergamon Press, GB, vol. 5, 1990, pp. 251-278, XP008054499. cited by applicant . Ratain M J et al., "Population Pharmacodynamic Study of Amonafide: A Cancer and Leukemia Group B Study," Journal of Clinical Oncology, Grune and Stratton, New York, NY, US, vol. 13, No. 3, Mar. 1995, pp. 741-747, XP008044974 ISSN: 0732-183X. cited by applicant . Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Aug. 1994, Yasuhara H: "Ethnic factors in evaluation of drug efficacy and safety," XP002350633 Database accession No. NLM7927070. cited by applicant . Setiabidu R et al., "Dapsone N-Acetylation, Metoprolol, Alpha-Hydroxylation, and S-Mephenytoin 4-Hydroxylation Polymorphisms in an Indonesian Population: A Cocktail and Extended Phenotyping Assessment Trail," Clinical Pharmacology & Therapeutics, Mosby-Year Book, St Louis, MO, US, vol. 56, No. 2, Aug. 1994, pp. 142-153, XP008044975 ISSN: 0009-9236. cited by applicant . "Helsinki Declaration" Online Ethics Center, [Online] Apr. 5, 2005, XP002350634 Retrieved from the Internet: URL:http://onlineethics.org/reseth/helsink i.html> retrieved on Oct. 25, 2005. cited by applicant . Castensen et al., "USP Dissolution IV:Comparison of Methods," J. Pham. Sci 1978, 67(9), pp. 1303-1307. cited by applicant . Encarta World English Dictionary [North American Edition] 2006 Microsoft Incorporation "Matrix", p. 1, definition 2, http://encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?- - refid=1861678516 retrieved on Apr. 30, 2006. cited by applicant . Wiktionary, "dispersed," p. 1, http://en.wiktionary.org/wiki/disperse retrived on Apr. 30, 2006. cited by applicant . Abraham Sunshine et al., "Analgesic Oral Efficacy of Tramadol Hydrochloride in Postoperative Pain," Clin. Pharmacol. Ther., vol. 51, Jun. 1992, pp. 740-746. cited by applicant . E.Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7,2 (1992), pp. 1-15, English translation. cited by applicant . Gourlay, et al., "Influence of a High-Fat Metal on the Absorption of Morphine From Oral Solutions," Clin. Pharmacol. Ther., vol. 46, Oct. 1989, pp. 463-468. cited by applicant . Geoffrey K. Gourlay, et al.,"The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symtoms Management, vol. 6., No. 7, Oct. 1991, pp. 431-436. cited by applicant . Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30. cited by applicant . Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J. (1991) 67 (Suppl. 2) pp. S50-S54. cited by applicant . Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824. cited by applicant . D.L. Munday, et al., "Changes in Drug Release Rate 2. Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60. cited by applicant . A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to MS Contin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company. cited by applicant . Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 2003. cited by applicant . Patient consent forms, apparently for four study participants, 2003. cited by applicant . Investigator agreements between the study organizers and certain of the principal investigators, 2003. cited by applicant . Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987, In Clinical Nursing Forum Supplement vol. 14 (2), p. 112, 1987. cited by applicant . J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Pain and Symptom Manag., vol. 4 (3), pp. 146-151,1989. cited by applicant . J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer Nursing, vol. 12 (4), pp. 202-208, (1989). cited by applicant . R.K. Kaiko, "The Pre- and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Pudue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989). cited by applicant . H.F. Stowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anesthesia, 1985, vol. 40, pp. 438-440. cited by applicant . MS Contin--Frequency of Daily Dosing, Jan.-Nov. 1990. cited by applicant . R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacolinetics and Pharmacodynamics of Kapanol.RTM. Capsules Given Every 24 hours and Every 12 hours with MS Contin.RTM. Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," Memorial Hospital IRB Protocol pp. 379-381, 1993. cited by applicant . 7th World Congress on Pain, Abstracts 997-1001, Aug. 26, 1993. cited by applicant . Advertisement: Raxanol SR., 1988 Roxane Labs, Inc. cited by applicant . T. Hunt and R. Kaiko, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults," Clin. Thera., vol. 13, No. 4, pp. 482-488, 1991. cited by applicant . S. Bloomfield, et al., "Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol,"Ther., vol. 53, No. 4, pp. 469-478, 1993. cited by applicant . Advertisement: MS Contin 1986, 1987 The Purdue Frederick Company. cited by applicant . Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980). cited by applicant . Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987). cited by applicant . McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984). cited by applicant . Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8, pp. 1249-1277 (1990). cited by applicant . Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993). cited by applicant . Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," vol. 20, No. 77, pp. 1179-1197 (1994). cited by applicant . Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Jull Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy of the DIE course "Pelletization Technology," Nov. 1992, 106 pages plus 3 appendices. cited by applicant . Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," Pharmaceutical Technology Europa, pp. 19-24 (Oct. 1994). cited by applicant . Maccarrone C. et al.,"Single Dose Pharmacokinetics of Kapanol.TM. a New Oral Sustained-Release Morphine Formulation," Clinical Drug Investigation 1994:7 (5) 262-274. cited by applicant . West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol.TM. capsules," (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Gourlay GK, et al., "A comparison of Kapanol.TM. (A new sustained release morphine formulation), MST Contius.RTM. and morphine solution in cancer patients: pharmacokinetics aspects," (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Cherry DA, et al., "A comparison of Kapanol.TM. (a new sustained release morphine formulation), MST Continus.TM. and morphine solution in cancer patients: Morphine metabolite profiles and renal function," (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Plummer JL, et al., "A comparison of Kapanol.TM. (a new sustained release morphine formulation) MST Continus.TM. and mophine solution in cancer patients: pharmcodynamic aspects," (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral mophine fornulation, Kapanol.TM. capsules," (Abstract 1001) International Association for the Study on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Cherry DA, et al., "Once a Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Gourlay, et al., "Once a Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, In the Treatment of Cancer Pain: Pharmacokinetic Aspects," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Broomhead, et al., "Kadian.TM./Kapanol.TM.--A Once Daily Mophine Formulation," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Onclology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Gourlay et al., "Proceedings of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients," Pharmacolinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993. cited by applicant . MS Contin--Frequency of Daily Dosing (NDTI)--Jun. 1991-May 1992. cited by applicant . Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp. 193-212. cited by applicant . Kaiko et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," Current Terapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878. cited by applicant . European Search Report issued in connection with European Application No. 10177508.8-2123 on Sep. 11, 2010. cited by applicant . "The Merck Manual," Merck and Co., p. 4711 (1989). cited by applicant . Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990). cited by applicant . Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425-435 (1999). cited by applicant . Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999). cited by applicant . Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In vivo Correlation" (FDA, 1997). cited by applicant . Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0-2123. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3. cited by applicant . Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011). cited by applicant . FDA Response to a Citizen Petition, Oct. 25, 2013. cited by applicant . Claims pending in U.S. Appl. No. 12/982,386 on May 7, 2014. cited by applicant . Claims pending in U.S. Appl. No. 14/094,968 on May 7, 2014. cited by applicant . Claims pending in U.S. Appl. No. 13/833,263 on May 7, 2014. cited by applicant . Zohydro ER Package Insert revised Oct. 2013. cited by applicant . Zohydro ER Hydrocodone Bitartrate Extended-Release (HC-ER) Dec. 7, 2012. cited by applicant . Advisory Committee Briefing Document, NDA 20-2880, Zohydro.TM. ER Hydrocodone Bitartrate Extended-Release Capsules, Anesthetic and Analgesic Drug Products Advisory Committee, Dec. 7, 2012. cited by applicant . Approval Package for NDA 20-616/5-001 (Kadian.RTM.), 1997. cited by applicant . Kadian.RTM. Prescribing Information 2006. cited by applicant . MS Contin.RTM. Prescribing Information 2012. cited by applicant . Oxycontin.RTM. Prescribing Information 2010. cited by applicant . Trandemate ER.RTM. Prescribing Information 2005. cited by applicant . Benziger, et al., "A Pharmacokinetic/Pharmacodynamic Study of Controlled-Release Oxycodone", 1997. cited by applicant . Amendment after final action under 37 C.F.R. .sctn. 1.116 filed in connection with U.S. Appl. No. 11/372,857 on Mar. 2, 2015. cited by applicant . Declaration under 37 C.F.R. .sctn. 1.132 by Gurvinder Singh Rekhi filed in connection with U.S. Appl. No. 11/372,857 on Mar. 6, 2015. cited by applicant . Declaration of Interference issued in connection with U.S. Appl. Nos. 11/372,857; 13/833,263 and 14/094,968 on Apr. 8, 2015. cited by applicant . Claims pending in U.S. Appl. No. 14/635,198 on Mar. 30, 2015. cited by applicant . Claims pending in U.S. Appl. No. 14/672,894 on Mar. 30, 2015. cited by applicant . Claims pending in U.S. Appl. No. 14/673,447 on Mar. 30, 2015. cited by applicant . Claims pending in U.S. Appl. No. 14/635,198 on Mar. 2, 2015. cited by applicant.

Primary Examiner: Sasan; Aradhana
Attorney, Agent or Firm: Davidson, Davidson & Kappel, LLC